Also, increased serum hepcidin levels were associated with metastasized disease and poor outcome in prostate, breast, colon and non-small cell lung cancer as well as renal cell carcinoma and non-Hodgkin lymphoma [1–3, 9–12]. This evidence concerns the gene HAMP and non-Hodgkin lymphoma.